Active substanceFluconazoleFluconazole
Similar drugsTo uncover
  • Vero-Fluconazole
    capsules inwards 
    VEROPHARM SA     Russia
  • Disorel-Sanovel
    capsules inwards 
  • Diflazon®
    solution d / infusion 
  • Diflucan®
    powder inwards 
    Pfizer Inc.     USA
  • Diflucan®
    capsules inwards 
    Pfizer Inc.     USA
  • Diflucan®
    solution in / in 
    Pfizer Inc.     USA
  • Micon
    solution d / infusion 
  • Medoflucon®
    capsules inwards 
    MEDSERV, LLC     Russia
  • Mycomomax®
    capsules inwards 
    Zentiva c.s.     Czech Republic
  • Mycosyst®
    capsules inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Mycosyst®
    solution d / infusion 
    GEDEON RICHTER, OJSC     Hungary
  • Mycoflucan®
    pills inwards 
  • Mycoflucan®
    solution d / infusion 
  • Nofung®
    capsules inwards 
  • Procanazole
    capsules inwards 
  • Fangifflu
    capsules inwards 
  • Flukozan
    solution d / infusion 
    LENS-PHARM, LLC     Russia
  • Flukoside
    capsules inwards 
  • Flukomabol®
    solution d / infusion 
    PREBAND PFC, LLC     Russia
  • Fluconazole
    capsules inwards 
  • Fluconazole
    capsules inwards 
    PHARMACY 36.6, CJSC     Russia
  • Fluconazole
    solution d / infusion 
  • Fluconazole
    capsules inwards 
  • Fluconazole
    solution d / infusion 
    RUSYUROFARM, LLC     Russia
  • Fluconazole
    capsules inwards 
    VALENTA PHARM, PAO     Russia
  • Fluconazole
    capsules inwards 
    REPLEK FARM Skopje, OOO     Macedonia
  • Fluconazole
    capsules inwards 
    FARMPROJECT, CJSC     Russia
  • Fluconazole
    solution d / infusion 
    EAST-FARM, CJSC     Russia
  • Fluconazole
    capsules inwards 
    OZONE, LLC     Russia
  • Fluconazole
    capsules inwards 
    BIOKOM, CJSC     Russia
  • Fluconazole
    capsules inwards 
    VERTEKS, AO     Russia
  • Fluconazole
    capsules inwards 
  • Fluconazole
    pills inwards 
    TECHNOLOG, JSC     Ukraine
  • Fluconazole
    capsules inwards 
    Hemofarm AD     Serbia
  • Fluconazole
    capsules inwards 
  • Fluconazole
    capsules inwards 
    Astrafarm, CJSC     Russia
  • Fluconazole
    capsules inwards 
    MEDISORB, CJSC     Russia
  • Fluconazole OBL
    capsules inwards 
  • Fluconazole Zentiva
    solution d / infusion 
    Zentiva c.s.     Czech Republic
  • Fluconazole Cabi
    solution d / infusion 
  • Fluconazole STADA
    capsules inwards 
  • Fluconazole-Acti
    solution d / infusion 
    Aktifarm, OOO     Russia
  • Fluconazole-Sandoz®
    capsules inwards 
    Sandoz d.     Slovenia
  • Fluconazole-Teva
    capsules inwards 
  • Flukonorm
    capsules inwards 
  • Flucorus®
    solution d / infusion 
    MS-VITA, LLC     Russia
  • Flukorem
    gel externally 
    REMEDIYA, LLC     Russia
  • Flucostat®
    solution d / infusion 
  • Flucostat®
    capsules inwards 
  • Forkan®
    solution d / infusion 
    Cipla Ltd.     India
  • Forkan®
    capsules inwards 
    Cipla Ltd.     India
  • Ciscan®
    capsules inwards 
  • Dosage form: & nbspcapsules
    Composition:

    Composition per one capsule: active

    substance: fluconazole - 50 mg or 150 mg;

    Excipients: starch potato - 43 mg or 129 mg,

    low molecular weight polyvinylpyrrolidone (povidone) 6 mg or 18 mg, magnesium stearate

    or calcium stearate 1.0 mg or 3.0 mg to obtaining a mass of contents of the capsule

    100 mg or 300 mg.

    The composition of the capsule shell No. 1:

    Capsule body:

    titanium dioxide - 1%, indigotine Е-132 - 0,1333%, gelatin - up to 100%.

    capsule cap:

    titanium dioxide - 1%, indigotin E-132 - 0.1333%, gelatin - up to 100%.

    The composition of the capsule shell No. 3: Capsule body:

    titanium dioxide - 2%, gelatin - up to 100%.

    Description:
    Capsules 50 mg:
    The size of the capsules is No. 3. The capsule case is white, the cap of the capsule is blue.
    Capsules 150 mg:
    The size of the capsules is No. 1. The capsule case is blue, the cap of the capsule is blue.
    The contents of the capsules are a granular powder of white or white with a slightly yellowish hue of color.

    Pharmacotherapeutic group:Antifungal agent.
    ATX: & nbsp

    J.02.A.C   Triazole derivatives

    J.02.A.C.01   Fluconazole

    Pharmacodynamics:
    Antifungal agent, has a highly specific effect, inhibiting the activity of enzymes of fungi, dependent on cytochrome P450. Blocking the conversion of lanosterol of fungal cells to ergosterol; increases the permeability of the cell membrane, disrupts its growth and replication.
    Fluconazole, being highly selective for cytochrome P450 fungi, practically does not inhibit these enzymes in the human body (in comparison with itraconazole, clotrimazole, econazole andketoconazole to a lesser extent suppresses oxidative processes dependent on cytochrome P450 in human liver microsomes). Does not have anti-androgenic activity.
    It is active in opportunistic mycoses, including those caused by Candida spp. (including generalized forms of candidiasis against immuno-depression), Cryptococcus neoformans and Coccidioides immitis (including meningitis and encephalitis), Microsporum spp. and Trichophyton spp; with endemic mycoses caused by Blastomyces dermatidis, Histoplasma capsulatum (including immunosuppression).
    Pharmacokinetics:
    After oral administration fluconazole well absorbed, food intake does not affect the rate of absorption of fluconazole, its bioavailability is 90%.
    The time of maximum concentration after ingestion, fasting 150 mg of the drug - 0.5-1.5 hours and 90% of the concentration in the plasma with intravenous administration at a dose of 2.5-3.5 mg / l. The half-life of fluconazole is 30 hours. The connection with plasma proteins is 11-12%. The concentration in the plasma is in direct proportion to the dose. 90% level of equilibrium concentration is reached by 4-5 days of treatment with the drug (with the administration of 1 time / day).
    The introduction of a "shock" dose (on the first day), which is 2 times greater than the usual daily dose, allows one to reach a concentration level corresponding to 90% of the equilibrium concentration by the second day.
    Fluconazole well penetrates into all body fluids.The concentration of the active substance in breast milk, articular fluid, saliva, sputum and peritoneal fluid is similar to that in blood plasma. Constant values ​​in the vaginal secretion are reached 8 hours after ingestion and are held at this level for at least 24 hours. Fluconazole well penetrates into the cerebrospinal fluid (CSF), with fungal meningitis
    as
    mainly kidney (80%
    in unchanged form, 11%
    the concentration in the CSF is about 85% of its plasma level. In the fluid, epidermis and stratum corneum (selective accumulation), concentrations exceeding serum levels are achieved. After ingestion of 150 mg on day 7, the concentration in the stratum corneum is 23.4 μg / g, and 1 week after the second dose, 7.1 μg / g; concentration in the nails after 4 months of use in a dose of 150 mg once a week - 4.05 μg / g in healthy and 1.8 μg / g in the affected nails. The volume of distribution approximates the total water content in the body. It is an inhibitor of the isoenzyme CYP2C9 in the liver. Displayed
    metabolites). The clearance of fluconazole is proportional to the clearance of creatinine (CC). Metabolites of fluconazole in peripheral blood were not detected.The pharmacokinetics of fluconazole significantly depends on the functional state of the kidneys, and there is an inverse relationship between the half-life and the clearance of creatinine. After hemodialysis for 3 hours the concentration of fluconazole in plasma is reduced by 50%.

    Indications:
    • cryptococcosis, including cryptococcal meningitis and other localizations of this infection (including lungs, skin), both in patients with normal immune response, and in patients with various forms of immunodepression (including AIDS patients, organ transplantation); the drug can be used to prevent cryptococcal infection in AIDS patients;
    • generalized candidiasis, including candidemia, disseminated candidiasis and other forms of invasive candidiasis infections (peritoneal, endocardial, eye, respiratory and urinary tract infections). Treatment can be performed in patients with malignant neoplasms, in intensive care units, in patients undergoing cytostatic or immunosuppressive therapy, and in the presence of other factors predisposing to the development of candidiasis;
    • - . from
    • Candidiasis of the mucous membranes, including oral cavity and pharynx (including atrophic candidiasis of the oral cavity, associated with the wearing of dentures), esophagus, non-invasive bronchopulmonary candidiasis, candiduria, candidiasis of the skin; prevention of recurrence of oropharyngeal candidiasis in AIDS patients;
    • - genital candidiasis: vaginal candidiasis (acute and chronic
    • relapsing), prophylactic use to reduce the frequency of recurrences of vaginal candidiasis (3 or more episodes per year); Candidiasis balanitis;
    • prevention of fungal infections in patients with malignant neoplasms that are predisposed to such infections as a result of
    • chemotherapy with cytostatics or radiation therapy;
    • mycosis of the skin, including mycosis of the feet, the body, the groin area; pityriasis (lichen colored) deprive, onychomycosis; candidiasis of the skin;
    • Deep endemic mycoses, including coccidiomycosis and histoplasmosis, in patients with normal immunity.

    Contraindications:
    • hypersensitivity to the drug (including other azole antifungal drugs in history);
    • simultaneous reception of terfenadine (against the background of a constant intake of fluconazole at a dose of 400 mg / day or more) orastemizole, as well as other drugs that extend the QT interval;
    • children's age up to 4 years.

    Carefully:
    Hepatic and / or renal failure, the appearance of rashes on the background of the use and fluconazole in patients with superficial fungal infection of potentially hepatotoxic drugs, potentially
    invasive / systemic fungal infections, concomitant administration
    proaritmogenic states in patients with multiple risk factors (organic heart diseases, electrolyte balance disorders, simultaneous intake of drugs that cause arrhythmias), pregnancy.

    Pregnancy and lactation:
    The use of the drug in pregnant women is inappropriate, with the exception of severe or life-threatening forms of fungal infections, when the potential benefit from the use for the mother significantly exceeds the risk to the fetus.

    Dosing and Administration:
    Inside.
    Adults and children over 15 years of age (body weight over 50 kg), with cryptococcal meningitis and cryptococcal infections of other locations on the first day, usually prescribed 400 mg (8 capsules of 50 mg), and then continue treatment at a dose of 200 mg (4 capsules of 50 mg) - 400 mg (8 capsules of 50 mg) once a day.The duration of treatment for cryptococcal infections depends on the clinical efficacy, confirmed by mycological examination; when cryptococcal meningitis treatment course should be at least 6-8 weeks.
    To prevent the recurrence of cryptococcal meningitis in AIDS patients, after completion of the full course of primary therapy, fluconazole prescribe a dose of 200 mg (4 capsules of 50 mg) per day for a long period of time.
    When candidemia, disseminated candidiasis and other invasive candidiasis infections on the first day of the dose is 400 mg (8 capsules of 50 mg), and then - 200 mg (4 capsules of 50 mg) per day. With insufficient clinical efficacy, the dose of the drug can be increased to 400 mg (8 capsules 50 mg) per day. The duration of therapy depends on the clinical effectiveness of the drug (100% of the recommended dose). With SC from 11 to 50 ml / min 50% of the recommended dose or usual dose is applied once in 2 days.

    Clearance

    Interval / daily '

    creatinine

    ; dose " '

    > 40 ml / min

    24 h 1 (normal dosing regimen)

    21-40 ml / min

    48 hours (1 time in 2 days) or half the usual


    daily dose (once every 24 hours)

    1 10-20 ml / min

    72 hours (G every 3 days)


    Patients regularly on dialysis,one dose of the drug is used after each session of hemodialysis. In oropharyngeal candidiasis, the drug is usually prescribed at 150 mg once a day, the duration of treatment is 7-14 days. If necessary, in patients with a pronounced decrease in immunity, treatment may be longer. For the prevention of recurrence of oropharyngeal candidiasis in AIDS patients after completing the full course of primary therapy, 150 mg once a week. In other cases of candidiasis (with the exception of the genital), for example, esophagitis, non-invasive bronchopulmonary injury, candiduria, candidiasis of the skin and mucous membranes, etc., the effective dose is usually 150 mg / day with a treatment duration of 14-30 days. For the prevention of candidiasis in a patient x with cancer the recommended dose of fluconazole amounts to 150-400 mg (3-8 capsules of 50 mg), 1 times a day depending on the degree of risk of fungal vaginal candidiasis infektsii.Pri fluconazole prescribe a dose of 150 mg (1 capsule of 150 mg or 3 capsules of 50 mg) once, inside. To reduce the frequency of recurrence of vaginal candidiasis -150 mg (1 capsule of 150 mg or 3 capsules of 50 mg) once a month for 4-12 months, sometimes you may need more frequent application. In candida balanitis - 150 mg (1 capsule of 150 mg or 3 capsules of 50 mg) once a day, once. For skin infections, including foot mycoses, inguinal skin and candidiasis, the recommended dose is 150 mg (1 capsule of 150 mg or 3 capsules 50 mg) once a week or 50 mg (1 capsule 50 mg) once a day, the dosing regimen depends on the clinical and mycological effect. The duration of therapy in usual cases is 2-4 weeks, however, with foot mycoses may require more long-term therapy (up to 6 weeks). In case of pityriasis - 300 mg (2 capsules of 150 mg or 6 capsules of 50 mg) once a week for 2 weeks, some patients require a third dose of 300 mg per week, while in some cases a single 300-400 mg dose is sufficient. With onychomycosis - 150 mg once a week; Treatment continues until the infected nail is replaced. To re-grow the nails on the fingers and toes, it normally takes 3-6 months and 6-12 months, respectively.
    Side effects:
    The undesirable phenomena presented below are listed depending on the anatomical and physiological classification and frequency of occurrence. Frequency of occurrence is defined as follows: often - more than 1%; infrequently, 0.1-1%; rarely - 0,01-0,1%; very rarely - less than 0.01%.
    On the part of the digestive system, loss of appetite, changes in taste, nausea, diarrhea, flatulence, abdominal pain, vomiting, abdominal pain, rarely - impaired liver function (jaundice, hepatocellular necrosis, hyperbilirubinemia, increased activity of alanine aminotransferase (ALT), aspartate aminotransferase (ACT) and alkaline phosphatase (APF), hepatitis, hepatonecrosis), including severe.
    From the nervous system: headache, dizziness, excessive fatigue, rarely - convulsions.
    From the hemopoiesis: rarely - leucopenia, thrombocytopenia (bleeding, petechiae), neutropenia, agranulocytosis.
    Allergic reactions: skin rash, rarely - multiforme exudative erythema (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), anaphylactoid reactions (including angioedema, face swelling, hives, itching of the skin).
    From the cardiovascular system: longer duration
    QT interval, ventricular fibrillation / flutter.
    Other: rarely - a violation of kidney function, alopecia, hypercholesterolemia, hypertriglyceridemia, hypokalemia.

    Overdose:
    Symptoms: hallucinations, paranoid behavior.
    Treatment: symptomatic (gastric lavage, forced diuresis).
    Hemodialysis within 3 hours reduces the plasma concentration by approximately 50%.
    Interaction:
    When using fluconazole with warfarin, prothrombin time increases (on average by 12%). In this regard, it is recommended to carefully monitor the prothrombin time in patients receiving the drug in
    combination with coumarin anticoagulants.
    Fluconazole increases the half-life of plasma from oral hypoglycemic agents - sulfonylurea derivatives (chlorpropamide, glibenclamide, glipizide, tolbutamide) in healthy people. Joint use of fluconazole and oral hypoglycemic agents in diabetic patients is allowed, but the doctor should keep in mind the possibility of developing hypoglycemia.
    The simultaneous use of fluconazole and phenytoin can lead to an increase in the concentration of phenytoin in the plasma to a clinically significant degree. Therefore, when it is necessary to jointly use these drugs, it is necessary to monitor the concentrations of phenytoin with correction of its dose in order to maintain the drug concentration within the therapeutic interval.The combination with rifampicin leads to a decrease in the area under the concentration-time curve (AUC) by 25% and a shorter half-life of fluconazole from the plasma by 20%. Therefore, patients receiving concomitantly rifampicin, it is advisable to increase the dose of fluconazole.
    It is recommended to monitor the concentration of cyclosporine in the blood in patients receiving fluconazole, because with the use of fluconazole and cyclosporine in patients with kidney transplantation, the use of fluconazole at a dose of 200 mg / day leads to a slow increase in the concentration of cyclosporine in the plasma.
    Patients who receive high doses of theophylline or who are likely to develop theophylline intoxication should be monitored for the early detection of symptoms of theophylline overdose, as taking fluconazole leads to a decrease in the average clearance rate of theophylline from the plasma.
    With the simultaneous use of fluconazole, terfenadine and cisapride, cases of unwanted reactions from the heart, including paroxysms of ventricular tachycardia (torsades des points), have been described.
    Simultaneous use of fluconazole and hydrochlorothiazide can lead to an increase in the concentration of fluconazole in blood plasma by 40%.
    There have been reports of interactions between fluconazole and rifabutin,
    accompanied by an increase in serum concentration of the latter. With simultaneous application of fluconazole and rifampumbin, cases of uveitis are described. It is necessary to carefully observe patients who simultaneously receive rifabutin and fluconazole.
    In patients receiving a combination of fluconazole and zidovudine, an increase in the concentration of zidovudine is observed, which is caused by a decrease in the conversion of the latter into its main metabolite, so the side effects of zidovudine should be expected to increase.
    Increases the concentration of midazolam, which increases the risk of developing psychomotor effects (more pronounced when fluconazole is administered orally than intravenously).
    Increases the concentration of tacrolimus, in connection with which, the risk of nephrotoxic action increases.

    Special instructions:
    Treatment should continue until the appearance of clinical-hematologic remission. Premature termination of treatment leads to relapse.
    In rare cases, the use of fluconazole was accompanied by toxic changes in the liver, including fatalities, mainly in patients with serious concomitant diseases.In the case of hepatotoxic effects associated with fluconazole, there was no apparent dependence on total daily dose, duration of therapy, sex and age of the patient. The hepatotoxic effect of fluconazole was usually reversible; signs of it disappeared after discontinuation of therapy. If there are clinical signs of liver damage that may be associated with fluconazole, the drug should be discontinued.
    Patients with AIDS are more likely to develop severe skin reactions with many drugs. In those cases where the rash develops in patients with superficial fungal infection and it is regarded as definitely associated with fluconazole, the drug should be discontinued. When rashes appear in patients with invasive systemic fungal infections, they should be carefully monitored and canceled fluconazole when there are bullous changes or erythema multiforme.
    Care should be taken when taking fluconazole simultaneously with cisapride, rifabutin, or other drugs metabolized by the cytochrome P450 system.

    Form release / dosage:Capsule of 50 mg and 150 mg
    Packaging:
    For 1, 3, 10 capsules with a dosage of 150 mg or 7, 10 capsules with a dosage of 50 mg in a contour mesh box made of a polyvinylchloride film and aluminum foil printed lacquered.
    By 1, 2, 3, 4 or 7 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

    Storage conditions:
    In a dry, the dark place at a temperature of no higher than 25 ° C.
    Keep out of the reach of children.

    Shelf life:3 years.
    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:LP-000220
    Date of registration:16.02.2011
    The owner of the registration certificate:Barnaul Plant of Medical Preparations, LLC Barnaul Plant of Medical Preparations, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp29.09.2015
    Illustrated instructions
      Instructions
      Up